{"id":21277,"date":"2024-11-08T10:58:50","date_gmt":"2024-11-08T10:58:50","guid":{"rendered":"https:\/\/makingpharmaindustry.it\/?p=21277"},"modified":"2024-11-07T11:08:30","modified_gmt":"2024-11-07T11:08:30","slug":"ensuring-excellence-in-aseptic-processing-key-highlights-from-eu-gmp-annex-1","status":"publish","type":"post","link":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/ensuring-excellence-in-aseptic-processing-key-highlights-from-eu-gmp-annex-1\/","title":{"rendered":"Ensuring excellence in aseptic processing: key highlights from EU GMP Annex 1"},"content":{"rendered":"

The rigorous standards set by regulatory guidelines ensure the consistent production of sterile products<\/strong> across the pharmaceutical industry. Central to this is the updated Annex 1 of the EU GMP guidelines, which outlines the critical aspects of production, from aseptic preparation to filter sterilization, emphasizing risk management and the adoption of new technologies.<\/p>\n

Defining aseptic preparation and processing<\/h2>\n

Aseptic processing is defined as the handling of sterile products, containers, and devices within a controlled environment where air supply, materials, and personnel are regulated to prevent microbial and particulate contamination. The recent updates in Annex 1 stress that every aseptic process should be comprehensively defined, including the identification and control of associated risks. Sites must ensure their Contamination Control Strategy (CCS)<\/strong> sets clear acceptance criteria, and methods are properly documented and implemented.<\/p>\n

Mitigating contamination risks<\/h2>\n

Minimizing the risk of contamination remains a priority, particularly during product preparation, processing stages, and before sealing in its final container. Cleanrooms should be designed to limit particulate generation. Equipment such as Restricted Access Barrier Systems (RABS)<\/strong>, isolators, and robotic automation are recommended to reduce human intervention in Grade A areas, minimizing contamination risk. For example, pre-sterilized and assembled equipment should be used whenever feasible, and operations requiring direct human involvement should be minimized through engineering solutions.<\/p>\n

Operational grades and their applications<\/h2>\n

Annex 1 provides detailed descriptions of operational grades used in aseptic processes:<\/p>\n

    \n
  • Grade A<\/strong>: The critical zone for tasks like aseptic filling, sealing, compounding, and loading of sterilizers.<\/li>\n
  • Grade B<\/strong>: The immediate background supporting Grade A.<\/li>\n
  • Grade C<\/strong>: Where the preparation of solutions occurs before filtration.<\/li>\n
  • Grade D<\/strong>: Used for the cleaning and handling of equipment pre-sterilization.<\/li>\n<\/ul>\n

    This structured approach ensures that operations are carried out under stringent environmental controls suited to each task\u2019s contamination risk level.<\/p>\n

    Guidelines for equipment and process integrity<\/h2>\n

    The integrity of the aseptic process<\/strong> is upheld by strict validation and monitoring protocols. For example, pre- and post-use integrity tests of sterilizing filters are mandated to verify effectiveness. Filters used for sterile filtration should undergo validation under worst-case conditions, employing bacterial retention testing to confirm sterility. This validation extends to assessing filter compatibility with the product to avoid compromising efficacy or safety.<\/p>\n

    Critical considerations for container closure<\/h2>\n

    Finishing processes, such as container sealing, also receive significant focus. Properly validated methods must ensure integrity during operations, with fusion-sealed containers like ampoules and BFS units subjected to 100% integrity testing. Large containers may follow a reduced sampling plan if justified by data. Importantly, visual inspection alone is insufficient; scientifically validated methods are essential.<\/p>\n

    Documentation and Risk Management<\/h2>\n

    Annex 1 emphasizes comprehensive documentation at every stage. Non-standard interventions during production should be recorded, assessed, and authorized by the quality unit. A robust defect library should be maintained to support operator training and quality assurance.<\/p>\n

    For aseptic operations, interventions must be carefully designed to limit contamination risks and documented for traceability. The guideline mandates that interventions\u2014whether corrective or inherent\u2014undergo risk assessments and be managed through the Pharmaceutical Quality System (PQS)<\/strong>.<\/p>\n

    The role of continuous monitoring<\/h2>\n

    Personnel and process behavior should be regularly observed by trained experts. Inappropriate practices should be identified and corrected promptly. This continuous review ensures the adherence to aseptic standards and fosters a culture of vigilance.<\/p>\n

    Conclusion<\/h2>\n

    The revisions in Annex 1 provide a comprehensive framework to strengthen aseptic processing across pharmaceutical facilities. By integrating technological advancements, adopting detailed risk management practices, and upholding stringent control measures, manufacturers can safeguard the production of high-quality, sterile products. The emphasis on contamination prevention, rigorous testing, and documentation underscores the dedication to patient safety and product excellence.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Annex 1 of the EU GMP guidelines enhances sterile product production by defining aseptic processes, emphasizing contamination control, equipment validation, and stringent documentation. It promotes risk managemen and the focus on comprehensive strategies and technology adoption ensures consistent high-quality outcomes in the pharmaceutical industry<\/p>\n","protected":false},"author":32,"featured_media":21278,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[810,821],"tags":[],"class_list":{"0":"post-21277","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-gmp-en","8":"category-guidelines"},"yoast_head":"\nEnsuring excellence in aseptic processing: key highlights from EU GMP Annex 1 - MakingPharmaIndustry<\/title>\n<meta name=\"description\" content=\"Annex 1 of the EU GMP guidelines enhances sterile product production by defining aseptic processes, emphasizing contamination control, equipment validation and stringent documentation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/ensuring-excellence-in-aseptic-processing-key-highlights-from-eu-gmp-annex-1\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ensuring excellence in aseptic processing: key highlights from EU GMP Annex 1 - MakingPharmaIndustry\" \/>\n<meta property=\"og:description\" content=\"Annex 1 of the EU GMP guidelines enhances sterile product production by defining aseptic processes, emphasizing contamination control, equipment validation and stringent documentation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/ensuring-excellence-in-aseptic-processing-key-highlights-from-eu-gmp-annex-1\/\" \/>\n<meta property=\"og:site_name\" content=\"MakingPharmaIndustry\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-08T10:58:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2024\/11\/AdobeStock_942981052-scaled.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1435\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Valentina Parrella\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Valentina Parrella\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/ensuring-excellence-in-aseptic-processing-key-highlights-from-eu-gmp-annex-1\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/ensuring-excellence-in-aseptic-processing-key-highlights-from-eu-gmp-annex-1\/\"},\"author\":{\"name\":\"Valentina Parrella\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/5e59d6ee887eb3eafd7887d214ff1a09\"},\"headline\":\"Ensuring excellence in aseptic processing: key highlights from EU GMP Annex 1\",\"datePublished\":\"2024-11-08T10:58:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/ensuring-excellence-in-aseptic-processing-key-highlights-from-eu-gmp-annex-1\/\"},\"wordCount\":601,\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/ensuring-excellence-in-aseptic-processing-key-highlights-from-eu-gmp-annex-1\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2024\/11\/AdobeStock_942981052-scaled.jpeg\",\"articleSection\":[\"GMP\",\"Guidelines\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/ensuring-excellence-in-aseptic-processing-key-highlights-from-eu-gmp-annex-1\/\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/ensuring-excellence-in-aseptic-processing-key-highlights-from-eu-gmp-annex-1\/\",\"name\":\"Ensuring excellence in aseptic processing: key highlights from EU GMP Annex 1 - MakingPharmaIndustry\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/ensuring-excellence-in-aseptic-processing-key-highlights-from-eu-gmp-annex-1\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/ensuring-excellence-in-aseptic-processing-key-highlights-from-eu-gmp-annex-1\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2024\/11\/AdobeStock_942981052-scaled.jpeg\",\"datePublished\":\"2024-11-08T10:58:50+00:00\",\"author\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/5e59d6ee887eb3eafd7887d214ff1a09\"},\"description\":\"Annex 1 of the EU GMP guidelines enhances sterile product production by defining aseptic processes, emphasizing contamination control, equipment validation and stringent documentation.\",\"breadcrumb\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/ensuring-excellence-in-aseptic-processing-key-highlights-from-eu-gmp-annex-1\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/ensuring-excellence-in-aseptic-processing-key-highlights-from-eu-gmp-annex-1\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/ensuring-excellence-in-aseptic-processing-key-highlights-from-eu-gmp-annex-1\/#primaryimage\",\"url\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2024\/11\/AdobeStock_942981052-scaled.jpeg\",\"contentUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2024\/11\/AdobeStock_942981052-scaled.jpeg\",\"width\":2560,\"height\":1435,\"caption\":\"Ai-driven drug discovery visualized with digital networks and capsules.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/ensuring-excellence-in-aseptic-processing-key-highlights-from-eu-gmp-annex-1\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/makingpharmaindustry.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ensuring excellence in aseptic processing: key highlights from EU GMP Annex 1\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/\",\"name\":\"MakingPharmaIndustry\",\"description\":\"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/5e59d6ee887eb3eafd7887d214ff1a09\",\"name\":\"Valentina Parrella\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"caption\":\"Valentina Parrella\"},\"url\":\"https:\/\/makingpharmaindustry.it\/en\/author\/valentina-parrella\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ensuring excellence in aseptic processing: key highlights from EU GMP Annex 1 - MakingPharmaIndustry","description":"Annex 1 of the EU GMP guidelines enhances sterile product production by defining aseptic processes, emphasizing contamination control, equipment validation and stringent documentation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/ensuring-excellence-in-aseptic-processing-key-highlights-from-eu-gmp-annex-1\/","og_locale":"en_US","og_type":"article","og_title":"Ensuring excellence in aseptic processing: key highlights from EU GMP Annex 1 - MakingPharmaIndustry","og_description":"Annex 1 of the EU GMP guidelines enhances sterile product production by defining aseptic processes, emphasizing contamination control, equipment validation and stringent documentation.","og_url":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/ensuring-excellence-in-aseptic-processing-key-highlights-from-eu-gmp-annex-1\/","og_site_name":"MakingPharmaIndustry","article_published_time":"2024-11-08T10:58:50+00:00","og_image":[{"width":2560,"height":1435,"url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2024\/11\/AdobeStock_942981052-scaled.jpeg","type":"image\/jpeg"}],"author":"Valentina Parrella","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Valentina Parrella","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/ensuring-excellence-in-aseptic-processing-key-highlights-from-eu-gmp-annex-1\/#article","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/ensuring-excellence-in-aseptic-processing-key-highlights-from-eu-gmp-annex-1\/"},"author":{"name":"Valentina Parrella","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/5e59d6ee887eb3eafd7887d214ff1a09"},"headline":"Ensuring excellence in aseptic processing: key highlights from EU GMP Annex 1","datePublished":"2024-11-08T10:58:50+00:00","mainEntityOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/ensuring-excellence-in-aseptic-processing-key-highlights-from-eu-gmp-annex-1\/"},"wordCount":601,"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/ensuring-excellence-in-aseptic-processing-key-highlights-from-eu-gmp-annex-1\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2024\/11\/AdobeStock_942981052-scaled.jpeg","articleSection":["GMP","Guidelines"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/ensuring-excellence-in-aseptic-processing-key-highlights-from-eu-gmp-annex-1\/","url":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/ensuring-excellence-in-aseptic-processing-key-highlights-from-eu-gmp-annex-1\/","name":"Ensuring excellence in aseptic processing: key highlights from EU GMP Annex 1 - MakingPharmaIndustry","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/ensuring-excellence-in-aseptic-processing-key-highlights-from-eu-gmp-annex-1\/#primaryimage"},"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/ensuring-excellence-in-aseptic-processing-key-highlights-from-eu-gmp-annex-1\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2024\/11\/AdobeStock_942981052-scaled.jpeg","datePublished":"2024-11-08T10:58:50+00:00","author":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/5e59d6ee887eb3eafd7887d214ff1a09"},"description":"Annex 1 of the EU GMP guidelines enhances sterile product production by defining aseptic processes, emphasizing contamination control, equipment validation and stringent documentation.","breadcrumb":{"@id":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/ensuring-excellence-in-aseptic-processing-key-highlights-from-eu-gmp-annex-1\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/ensuring-excellence-in-aseptic-processing-key-highlights-from-eu-gmp-annex-1\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/ensuring-excellence-in-aseptic-processing-key-highlights-from-eu-gmp-annex-1\/#primaryimage","url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2024\/11\/AdobeStock_942981052-scaled.jpeg","contentUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2024\/11\/AdobeStock_942981052-scaled.jpeg","width":2560,"height":1435,"caption":"Ai-driven drug discovery visualized with digital networks and capsules."},{"@type":"BreadcrumbList","@id":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/ensuring-excellence-in-aseptic-processing-key-highlights-from-eu-gmp-annex-1\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/makingpharmaindustry.it\/en\/"},{"@type":"ListItem","position":2,"name":"Ensuring excellence in aseptic processing: key highlights from EU GMP Annex 1"}]},{"@type":"WebSite","@id":"https:\/\/makingpharmaindustry.it\/en\/#website","url":"https:\/\/makingpharmaindustry.it\/en\/","name":"MakingPharmaIndustry","description":"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/5e59d6ee887eb3eafd7887d214ff1a09","name":"Valentina Parrella","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","caption":"Valentina Parrella"},"url":"https:\/\/makingpharmaindustry.it\/en\/author\/valentina-parrella\/"}]}},"_links":{"self":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/21277","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/comments?post=21277"}],"version-history":[{"count":3,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/21277\/revisions"}],"predecessor-version":[{"id":21281,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/21277\/revisions\/21281"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media\/21278"}],"wp:attachment":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media?parent=21277"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/categories?post=21277"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/tags?post=21277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}